Loading patent…
OwnerJames Varani, Gary J. Fisher +1inventors
InventorsJames Varani, Gary J. Fisher, John J. Voorhees
Estimating the term…
The invention is based on selective inhibition of the enzyme (MMP-1), which causes the dermal matrix damage in humans, while sparing the enzyme(s) (MMP-9 and perhaps MMP-2) which not only do not cause the damage (based on extrapolation from our in vitro collagen gel system to real skin) but actually “clear away” the damage produced by MMP-1 to restore normal function to the skin. Matrix metalloproteinase-1 (MMP-1; fibroblast collagenase) is induced by UV radiation from the sun and is naturally elevated in old age. Human fibroblasts exposed to the degradation products of MMP-1 contract collagen, but when this debris is removed from their environment, the fibroblasts behave normally. Inhibiting MMP-1 but sparing enzymes that remove the debris improves human skin after onslaught from solar UV radiation, old age, and acne.
A topical composition for protecting human skin from collagen degradation, comprising a compound selective for the inhibition of at least one of MMP-1, MMP-8, and MMP-13 with respect to MMP-9 and optionally MMP-2, and a dermatologically suitable carrier therefor.
A method for restoring collagen and fibroblast proliferation in chronologically aged skin, comprising topically apply a compound selective for the inhibition of at least one of MMP-1, MMP-8, and MMP-13 with respect to MMP-9 and optionally MMP-2, and a dermatologically suitable carrier therefor.
A method for preventing collagen degradation and improving procollagen biosynthesis inhibition in human skin due to exposure of said skin to UV radiation, comprising topically applying a compound selective for the inhibition of at least one of MMP-1, MMP-8, and MMP-13 with respect to MMP-9 and optionally MMP-2, and a dermatologically suitable carrier therefor, between 24 hours prior to said exposure to twelve hours after said exposure.
A method for treating acne, comprising topically applying a compound selective for the inhibition of at least one of MMP-1, MMP-8, and MMP-13 with respect to MMP-9 and optionally MMP-2, and a dermatologically suitable carrier therefor.
Dependencies are inferred from the claim text.